It's all about Admedus today

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

02 October 2014, 10:05 AM

Sectors Covered:

Healthcare, Life Sciences

Admedus (AHZ) is due to announce the final results from its Phase 1 Herpes vaccine study today, with the primary endpoint of safety being achieved.

Here is my recent video interview with Admedus CEO Lee Rodne. More news to come...

AHZ is in our high conviction list. We have an Add recommendation on the stock and a share price target of $A0.23.

More information

Morgans clients can access detailed research on Admedus (AHZ). If you are interested in finding out more, please contact your nearest Morgans office

Disclaimer(s): Morgans was Lead Manager to the SPP and Placement and earned fees in this regard. 

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.